INDERAL LA
Pronunciation: proe-PRAN-oe-loel

What it isLong-acting beta-1, beta-2, and cardiac sodium-channel antagonist; hypertension and migraine prevention.
Why this oneIts CNS penetration and broad use for tremor, migraine, and adrenergic symptoms distinguish it from selective beta blockers.
What limits itBradycardia and bronchospasm limit use; it masks hypoglycemia and must be tapered to avoid rebound adrenergic effects.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Hypertension | Adults | 80 mg QD | 120–160 mg QD | 640 mg/day |
| Angina pectoris | Adults | 80 mg QD | 160 mg QD | 320 mg/day |
| Migraine prophylaxis | Adults | 80 mg QD | 160–240 mg QD | |
| Hypertrophic subaortic stenosis | Adults | 80–160 mg QD |
Titration Angina: increase gradually at 3–7 day intervals; migraine: increase gradually (assess over 4–6 weeks).
Renal Use with caution in impaired renal function.
Hepatic Use with caution in impaired hepatic function.
Available strengths
Pregnancy Pregnancy Category C; IUGR, small placentas, and neonatal bradycardia/hypoglycemia/respiratory depression reported.
Lactation Undefined.
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 60 mg | ER cap | 30 qd | $5.10 | offered |
| 80 mg | ER cap | 30 qd | $5.72 | offered |
| 120 mg | ER cap | 30 qd | $5.87 | offered |
| 160 mg | ER cap | 30 qd | $9.15 | offered |
Other forms: Propranolol (INDERAL)
NO BOXED WARNINGS
Principal riskAngina or MI after abrupt withdrawal